{
    "organizations": [],
    "uuid": "b442b0952e0e1a1f7aa81d61203d6ab2b554704d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-uniqure-presents-new-data-in-hemop/brief-uniqure-presents-new-data-in-hemophilia-b-patients-idUSFWN1SS0H6",
    "ord_in_thread": 0,
    "title": "BRIEF-Uniqure Presents New Data In Hemophilia B Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Uniqure NV:\n* UNIQURE PRESENTS NEW DATA DEMONSTRATING CLINICAL BENEFIT IN HEMOPHILIA B PATIENTS WITH PRE-EXISTING ANTI-AAV5 NEUTRALIZING ANTIBODIES\n* UNIQURE NV - NEW DATA FURTHER DEMONSTRATING FAVORABLE IMMUNOGENICITY PROFILE OF AAV5\n* UNIQURE NV - DATA SUGGEST AAV5 GENE THERAPIES MAY BE VIABLE TREATMENTS FOR AT LEAST 97% OF PATIENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T19:08:00.000+03:00",
    "crawled": "2018-05-22T19:21:38.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "uniqure",
        "nv",
        "uniqure",
        "present",
        "new",
        "data",
        "demonstrating",
        "clinical",
        "benefit",
        "hemophilia",
        "b",
        "patient",
        "neutralizing",
        "antibody",
        "uniqure",
        "nv",
        "new",
        "data",
        "demonstrating",
        "favorable",
        "immunogenicity",
        "profile",
        "aav5",
        "uniqure",
        "nv",
        "data",
        "suggest",
        "aav5",
        "gene",
        "therapy",
        "may",
        "viable",
        "treatment",
        "least",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}